关于专利与专利纠纷：肿瘤坏死因子α专利档案。第1部分：修美乐。

Of patents and patent disputes: The TNFα patent files. Part 1: Humira.

作者信息

Storz Ulrich

出版信息

Hum Antibodies. 2017;25(1-2):1-16. doi: 10.3233/HAB-160300.

PMID:27792008

Abstract

This article discusses the patent strategy underlying the world's best selling drug, AbbVie's Humira®. Despite a non-optimal starting position, AbbVie has established an extensive portfolio to fend off biosimilar competition. This article is the first part of a trilogy that discusses IP issues related to anti-Tumor Necrosis factor α (TNFα) biologics.

摘要

本文讨论了全球最畅销药物艾伯维公司的修美乐（Humira®）背后的专利策略。尽管起始位置并非最优，但艾伯维已建立了广泛的专利组合以抵御生物类似药的竞争。本文是讨论与抗肿瘤坏死因子α（TNFα）生物制剂相关知识产权问题的三部曲的第一部分。